As DPP-4 inhibition mainly supports physiological roles of endogenous GLP-1, these inhibitors may be of significant relevance in curing T2DM or even pre-diabetes, but this remains to be confirmed in comprehensive clinical trials. The gene discussed is GLP1R; the disease is diabetes mellitus.